ZEISS FOR EYE CARE PROFESSIONALS

ZEISS MyoCare lenses

A better outlook on life.

Our most effective lens designs aimed to slow myopia progression. MyoCare is backed by ZEISS innovation and more than a decade of experience in developing lenses to manage myopia progression.

Get in touch

Effective myopia management in children
Good vision for all viewing angles
Comfortable vision
Full UV protection

The two designs in ZEISS MyoCare portfolio include

ZEISS MyoCare lenses

A hard design variant with a smaller clear zone and stronger mean addition power that is suitable for example, younger children where progression is more rapid.
Central clear zone of 7 mm

Mean additional surface power of +4.6 D

Fill factor of 0.5
ZEISS MyoCare S lenses

Have a larger central clear zone with a softer mean addition power that is more suitable for example older children and adolescents, where progression is slower and where there is a need for easier adaptation.
Central clear zone of 9 mm

Mean additional surface power of +3.8 D

Fill factor of 0.5

Myopia is a growing concern worldwide

50 %

of the world’s population may be myopic by 2050.¹
~ 90 %

of young people in urban areas in Asia below the age of 20 are myopic.²
> 2 decades

of basic and clinical research and the successful application of Myopia Management lens solutions in East Asia.
In 2014

ZEISS began its partnership with the LIFE Child study to monitor refractive development in Caucasian children.
> 1.3 M

data points collected in the Euronet Market Research over the past 20 years from more than 400 real-world eye care practices distributed over Germany.

Young brown-haired girl without glasses rubbing her eyes while reading a book.

One problem – many solutions.

Optical, medical and behavioural treatments.

Because of its multifactorial causes, there's no one-and-only treatment for myopia. In fact, there are many treatment options on the market including optical, medical and behavioural treatments.
The choice of myopia treatments for children should be based on the age of onset, and axial length or refraction at a given age, along with knowledge of their individual rate of progression and overall risk profile. Comprehensive myopia treatments include a combination of lifestyle advice, a refractive correction method for full-time use, and myopia control methods to reduce or eliminate further progression.

More information

3D illustration of specialized rigid contact lens for the night.

Orthokeratology for progressive myopia

Specialised rigid contact lenses are worn overnight to allow clear vision during the day. Corneal reshaping effectively corrects refractive errors while slowing down axial elongation. Its effects may vary from day to day.

Soft contact lenses

Dual-focus soft contact lens designs are worn during the day. The soft contact lenses feature concentric optical zones that simultaneously create foveal correction and retinal myopic defocus.

Spectacle kids lenses with black, red, and soft pink frame with hearts.

Spectacle lenses

The least invasive and most accessible method for correcting myopia. The advantage of special spectacle lens designs is that it corrects vision and controls the progression of myopia at the same time. New generation spectacle lenses utilise optical microstructures which positively contributes to myopia progression management. Spectacle lenses are easy to wear, affordable, and mostly well accepted and tolerated, making it the most practical solution.

Pharmaceutical methods

This involves the application of pharmaceuticals. Pharmaceutical methods (e.g. low doses of atropine) are reportedly effective in managing myopia progression.

3D illustration of a black and white football.

Outdoor activities

Frequent outdoor activity is recommended to prevent or delay the onset of myopia. This equates to a minimum of 2 hours of intermittent outdoor time per day including additional outdoor time after school.³

ZEISS MyoCare lenses in a beige rose frame are shown on a light blue balloon. In the background is another slightly darker blue balloon.

A new lens design.

Creating simultaneous competing defocus.

Our latest lens designed to manage progressive myopia in children, is built on more than a decade of ZEISS innovation and experience in myopia management, in collaboration with optical experts such as material and vision scientists, eye care practitioners and academics. The design of ZEISS MyoCare lenses incorporates scientific concepts from proven scientific research, evidence-based learnings and effective treatments, including orthokeratology, soft multifocal contact lenses, science and the new generation of spectacles.

Finding the right balance.

The perfect combination of distinct optimisation parameters and a specific design.

An effective myopia mangement lens must overcome certain design challenges and find the optimum balance between myopia progression management and good vision. For this we have included the following in our ZEISS myopia management solutions:

A central zone small enough to establish an effective functional zone projecting myopic defocus on the near periphery close to the fovea
A mean addition surface power to induce the intended relative myopic defocus
A carefully selected fill factor to deliver high efficacy while preserving good wearability

ZEISS C.A.R.E. technology.

Cylindrical Annular Refractive Elements.

Introducing C.A.R.E.^® technology – aimed to deliver a “stop signal” to slow down progression of axial elongation. It consists of alternating defocus and correction zones in a ring-like pattern on the front surface, expanding towards the periphery of the lens.

The way to manage the location and alternation of both, the correction and functional elements through the entire front lens surface, is key to preserve the wearability. The ratio between these two elements within the functional zone is described by the so-called fill factor, i.e., the distribution of defocusing elements and correction sections and MyoCare and MyoCare S lenses adopt a fill factor of 0.5.

2 girls and 1 boy wearing ZEISS MyoCare lenses. They are looking at a plant, two of the three kids are looking at the plant through magnifying glasses.

ZEISS ClearFocus design^®.

Addressing the constant movement of the eyes.

Spectacle lenses must consider the moving eye behind the lens to ensure that the intended correction and myopic defocus is maintained for all gaze angles. With the ZEISS ClearFocus design^®, both the optimal refractive correction according to the patient’s refractive demands and the intended myopic defocus are maintained for all gaze directions. This is important not only for distinct viewing behaviours through the central clear zone when pursuing a focused task, but also for unintended gazes and saccades to the lens periphery.

In addition to that, the ZEISS ClearFocus design^® effectively minimises the induction of hyperopic defocus as opposed to typical spherical single vision lenses.

More information

Two line graphs that show the comparative mathematical simulation of spherical single vision lenses (in red) and MyoCare lenses (in blue). — Comparative mathematical simulation of spherical single vision lenses (in red) and MyoCare lenses (in blue)

ZEISS ClearFocus design aimed to effectively minimize the induction of hyperopic defocus.

The spherical error on spherical single vision lenses becomes obvious at about 10 mm distance from the lens centre, with increasing negative power towards the outer lens perimeter, thereby inducing hyperopic defocus.

In contrast to traditional spherical lens designs, ZEISS MyoCare lenses exhibit a flat and almost invariant spherical error throughout the lens, ensuring that the focus remains close to the intended focus shell, i.e., close to the retina. With increasing eccentricity from the lens centre, the spherical error even grows slightly more positive, inducing relative myopic defocus.

In summary, the ZEISS ClearFocus design featured in MyoCare^® lenses effectively minimizes unwanted hyperopic defocus for all viewing angles.

Three images depicting developmental milestones. On the left, a baby is placed on a scale by a healthcare practitioner; in the middle a boy is measured against a length chart on the wall; and on the right a girl is receiving an eye test.

A new approach to measure effectiveness.

Emmetropic progression ratio.

Each myopia progression management intervention has its own advantages and disadvantages, however each option pursues a common target: To slow down myopia progression.

Developmental milestones offer important insights into a child's developmental health. Reaching specific milestones at a given age shows a child is developing as expected. A comparison between the normal physiological growth and the patient’s current growth is needed to observe whether there is some type of non-physiological deviation present.

The ZEISS MyoCare shows an average emmetropic progression ratio for axial length with an average of 70% and ZEISS MyoCare S an average of 68%.⁴

A line graph that shows the annual reduction in progression of axial length – baseline by age.

Age-normal physiological growth curves.

It is not different when it comes to vision development. Here the focus is on the difference between the physiological elongation of the eye and the non-physiological (myopic) elongation, in other words, how far the child’s current status is from the age-normal physiological growth for emmetropic children. The aim is to follow or to be as close as possible to the age-normal physiological growth curves of emmetropic children.

The physiological emmetropic curve in the graph acts as the baseline value used as the reference to evaluate treatment effectiveness of our myopic progression intervention, MyoCare.

A line graph that displays annual progression of axial length showing physiological emmetropic growth in black at the bottom, myopic growth in red on top, and the results for ZEISS MyoCare lenses in blue in the middle. From this graph it can be deduced that myopia progression is below the myopic growth curve if ZEISS MyoCare lenses are worn.

Emmetropic progression ratio as a percentage of effectivity.

Once the treatment baseline is established, the emmetropic progression ratio is the parameter for the indication of how close children with the intervention are coming to the emmetropic growth curve in contrast to the myopic growth curve.

The aim is to get the absolute reduction curve of the myopia management solution (blue line) as close as possible to the physiological emmetropisation curve (black line) in contrast to the myopic curve (red line).

The emmetropic growth ratio is calculated with a specific formula.

ZEISS MyoCare designs effectively slow down myopia progression to come closer to the physiological growth curve.⁴

A portrait photograph of a young boy wearing glasses, with another portrait photograph of an older girl wearing glasses next to it. Below the two portrait shots are various spectacle frames and lenses.

Myopia management lens solutions, because every child is unique.

ZEISS MyoCare and ZEISS MyoCare S

When it comes to ensuring treatment success, compliance is key. That's why it's crucial for eye care providers to choose a strategy that emphasizes high wearability and comfort. By selecting an approach that patients will find easy and comfortable to use, you can help to ensure optimal results and patient satisfaction:

MyoCare^® a hard design variant with a smaller clear zone and stronger mean addition power that is suitable for example, younger children where progression is more rapid.
MyoCare^® S has a larger central clear zone with a softer mean addition power that is more suitable for example older children and adolescents, where progression is slower and where there is a need for easier adaptation.

Why MyoCare^® lenses should be your choice.

Vision as good as with single vision lenses.

95 %

of children wearing ZEISS MyoCare or ZEISS MyoCare S confirmed that they adapted to the lenses within 3 days.⁵
92 %

of all participants subjectively rated vision with ZEISS MyoCare as very good for far distances.⁵
94 %

rated MyoCare and MyoCare S lenses as very good for near distances.⁵

  
      MyoCare® portfolio
      
    A better outlook on life.

Third-party Content Blocked

The video player is blocked due to your tracking preferences. To change the settings and play the video, please click the button below and consent to use of "Functional" tracking technologies.

ZEISS C.A.R.E. technology (Cylindrical Annular Refractive Elements)

Alternating defocus and correction zones in a ring-like pattern on the front surface, expanding towards the periphery of the lens. These microstructures deliver a “stop signal” to slow down progression of axial elongation.⁶
ZEISS ClearFocus design^®

Aimed to remove the growth signal, the optimised back surface minimises hyperopic defocus in the periphery of the lens. Both the refractive correction as well as intended myopic defocus of the patient is maintained for all gaze directions. This technology supports the effectivity and wearability of ZEISS MyoCare lenses.

¹
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S, Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050, Ophthalmology. 2016;123(5):1036–1042.
²
Chen M, Wu A, Zhang L, et al. The increasing prevalence of myopia and high myopia among high school students in Fenghua city, eastern China: a 15-year population-based survey. BMC Ophthalmol. 2018;18(1):159. doi: 10.1186/s12886-018-0829-8.
³
Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, Lv M, He X, Xu X. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017; 9 5 ( 6 ):551- 5 6 6 . d o i: 10 .1111/ a o s .13 4 0 3.
⁴
Ohlendorf, A., et al. (2024, May 5-9). Myopia control efficacy through Emmetropic Progression Ratio:1-year of spectacle wear with cylindrical annular refractive elements (CARE)
[Conference presentation abstract]. The Association for Research in Vision and OpthalmologyOphthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
EPR for ages 7-12 year old children as sample size for ages 6 and 13 was small. When the entire sample of 6 to 13 years were considered, EPR for ZEISS MyoCare was 71%.
⁵
Two-year prospective, multi-center, double-blind, randomized controlled clinical trial lead by Tianjin Eye Hospital Optometric Center, China, 2022, on 80 myopic children wearing ZEISS MyoCare Rx lenses, 80 myopic children wearing ZEISS MyoCare S Rx lenses and80 Myopic children wearing ZEISS Single Vision lenses. 12-months interim results presented at ARVO 2024.
⁶
Hong Kong Polytechnic University owns granted patents (including Chinese patent: CN103097940) on annular concentric lens for myopia control, which are licensed to Carl Zeiss. Carl Zeiss started in 2021 to develop in collaboration with Wenzhou Medical University the latest cylindrical annular refractive elements technology for spectacle lenses that is used in MyoCare lens designs.

ZEISS MyoCare lenses

A better outlook on life.

The two designs in ZEISS MyoCare portfolio include